Abstract
INTRODUCTION
The use of 'durable' long-term mechanical circulatory support in children in the form of a ventricular assist device (VAD) improved survival among those on the heart transplant waiting list [1] . The Berlin Heart EXCOR V R has been the mainstay of long-term VAD support for children [2, 3] . One of the major limitations of this device is the high risk of thromboembolic events and the remarkable difficulties in adjusting anticoagulation treatment in infants. Due to the paracorporeal design, patients have been discharged from the hospital only in exceptional cases. One of the devastating complications includes cerebrovascular accidents, such as stroke or haemorrhage, which are reported in 6-62% of patients [4] [5] [6] [7] . In recent years, a reasonable number of reports of adults supported with continuous-flow (CF) left ventricular assist devices (LVADs), designed for patients with a body surface area (BSA) >1.2 m 2 , have been published [8, 9] . This step has led to improved survival and freedom from stroke and from device malfunction [10] . Data from the Interagency Registry for †The first two authors contributed equally to this work.
Mechanically Assisted Circulatory Support (INTERMACS) have shown a significant decrease in neurological dysfunction with continuous-flow ventricular assist devices (CFVADs) compared with pulsatile VADs in adults [11] . Because of the obvious advantage of discharging patients on VAD support to home and the observed tendency of patients to resume regular daily activities, these devices have been adopted for paediatric use [12] [13] [14] [15] [16] [17] [18] [19] [20] . In the search for anatomical boundaries, the recommended cut-off value of 1.2 m 2 was exceeded. Although implantation in smaller children is feasible from a technical standpoint, few data exist on the outcome, especially on the incidence of cerebral strokes in young patients. One may speculate that in children, where flow rates in the VAD might be lower than in adults, pump thrombosis and thromboembolic events might occur more often. The largest global registry for mechanical circulatory support in children is the Paediatric Interagency Registry for Mechanical Circulatory Support (PediMACS) database, which includes only US patients. Their 2015 report, which focused on children with CFVADs, included 109 patients from 35 hospitals, stated that cerebrovascular stroke or haemorrhage occurred in 26% of patients but without stratification to the body weight or the BSA [21] .
Our goal was to investigate ischaemic and haemorrhagic strokes in children supported with intracorporeal CFLVADs based on BSA, using the largest European VAD database [European Registry for Patients with Mechanical Circulatory Support (EUROMACS)]. The aim of this study was to determine the outcome of CFLVADs in children and report the adverse events by focusing on cerebral strokes. This information seems critical for counselling families prior to implantation and managing patients while they are on the device.
METHODS
EUROMACS is an official committee of the European Association for Cardiothoracic Surgery (EACTS). It was created to evaluate the characteristics of implantation and long-term survival and the complications faced by recipients of VADs. EUROMACS contains the data entries of patients of all ages. Data collection continues through the period of implantation of a VAD and concludes with the explantation of the VAD. The EUROMACS database has been designed so that the patient and the device outcomes are comparable with the INTERMACS database. In the meantime, EUROMACS also contributes data to the International Society for Heart and Lung Transplantation Registry for Mechanically Assisted Circulatory Support (IMACS 
Study variables
The primary variable was survival until either transplant or recovery. The secondary variables included cerebral strokes and pump thrombosis requiring either pump exchange or conservative treatment. Cerebral stroke was defined by the occurrence of an ischaemic or a haemorrhagic stroke, which was confirmed by neuroimaging.
Statistical analysis
The data are presented as mean ± standard deviation or as a frequency in percentage form. Comparisons were performed using the Student's t-test, the Mann-Whitney U-test and the Fisher's exact test. Overall, survival and freedom from cerebrovascular events were presented as the Kaplan-Meier curves and compared between the groups using the log-rank test. In addition, the cumulative incidence functions of these competing risks were presented. 
Data quality checks and audits
The EUROMACS Registry applies several methods to ensure the best quality data and to exclude the under-reporting of poor outcomes. Analyses of incoming data are conducted on a regular basis. In addition, individual hospitals are approached, and guidance is offered to complete or correct their data. Entries are adapted to adhere to the standard. Twice a year, each centre receives a file in which an overview of patients whose statuses need to be updated and whose changes/answers have to be monitored is presented. A couple of consistency and plausibility checks are performed, and the rendered files containing the inconsistent data of the participating centres are recorded. The data that are not plausible require checking and confirmation by the participating centres. The average number of follow-up records per patient is calculated on a per-centre basis and serves as an indicator for homogeneity and completeness of recording. The participating centres undergo random audits.
RESULTS

Patient population
Of the 2941 patients listed in the database as of 30 June 2016, 124 patients at 25 centres (Table 1) were under 19 years of age at the time of implant. Patients on a pulsatile device, biventricular support, extracorporeal centrifugal devices or unspecified implanted devices or those who had missed follow-up visits were excluded. The study group comprised 51 patients (27 boys and 24 girls) from 10 centres. The ethnicity of the patients included 40 Whites, 6 Asians, 2 African Americans and 3 non-defined ethnicities. Dilated cardiomyopathy was the leading underlying disease (Table 2) . Six children were on extracorporeal membrane oxygenation, and 88% of all patients were supported on inotropes prior to placement of the VAD. The patients were supported with HeartMate II (Thoratec Corp., Pleasanton, CA, USA; n = 6), HeartAssist 5 (MicroMed, Houston, TX, USA; n = 2) and HeartWare hVAD (HeartWare Ltd, Framingham, MA, USA; n = 42) (see Supplementary Material, File S1 
Outcomes
The mean age at the time of the implant was 13.8 years (range 5-18 years). Three children required a right VAD postoperatively: 1 in Group 1 (the patient died of an infection) and 2 in Group 2.
The mean stay in the intensive care unit ranged from 3 days to 12 days with no differences between the groups (mean stay in the intensive care unit was 23.3 days vs 29.2 days). Thirty-seven (72%) patients were discharged either to their homes or to a rehabilitation facility. The mean support time was 8.4 months (8-1363 days). Forty-three (84%) children survived until transplant or recovery or are on support (Figs 1 and 2 ). Eight (16%) patients died while on support within the observed follow-up time: 3 from Group 1 (23%) and 5 from Group 2 (13%). The reasons for their deaths are presented in Table 4 . At 12 months, 89% of the patients had received a transplant, were on support or had been successfully weaned from the device. Two late deaths occurred in patients who were on support for almost 2 years (716 days) or more (762 days). Right ventricular failure (1 in each group) and a cerebrovascular accident were the reasons for the late deaths. Twenty-four (47%) children underwent transplants. The mean waiting time was 250 days (range 8-1033 days). An LVAD was explanted from only 1 patient due to myocardial recovery.
There were no differences between the groups regarding survival (P = 0.21; Fig. 2) , transplant or recovery. In Group 1, 54% had transplants, whereas in the older age group, 55% had transplants within the observational period (P = 0.29).
Four (7%) children had pump thromboses: 1 in Group 1 and 3 in Group 2 (Table 5) . However, there were no differences in the estimated flow rate between the groups (4.1 l/min vs 3.6 l/min; Table 5 ).
Anticoagulation
A majority of the patients (n = 25) were taking anticoagulation medication prior to implantation of the LVAD: 14 patients were taking heparin, 7 received antiplatelet treatment, 4 were taking oral anticoagulants and in 2 patients these details were unknown. Twenty-four patients did not receive anticoagulant agents prior to LVAD placement. Two patients in the whole cohort tested positive for heparin-induced thrombocytopenia prior to LVAD implantation. One of the patients died of cerebral stroke. After implantation of the LVAD, all of the patients received either heparin (n = 49) or an alternative (n = 2). Only a minority (38%) received additional antiplatelet therapy including aspirin, clopidogrel or dipyridamole. The target 'international normalized ratio' values ranged from 2 to 3.5. No significant differences were seen among the groups.
Cerebral strokes
Overall, 4 cerebral stroke events (0.1 events per patient-year) were observed in Group 2 without reaching significance (P = 0.26). Cerebral strokes occurred between 19 days and 524 days on support (mean = 244 days). All but 1 patient died of this event; 1 patient underwent a transplant. Cerebral strokes were preceded by a history of or a current event comprising pump thrombosis in 3 patients. None of the patients on extracorporeal membrane oxygenation prior to VAD implantation experienced a stroke. Among the early deaths after LVAD implantation, all patients except 1patient were extubated. In this 1 patient, there were no clear clinical signs of severe brain damage.
DISCUSSION
Ischaemic or haemorrhagic strokes are devastating complications for patients on VAD support. Different reports use disparate definitions for these types of complications. INTERMACS and PediMACS use the term 'neurologic event rates', whereas a EUROMACS report uses the term 'neurologic dysfunction'. Other reports use the term 'cerebrovascular accidents'. One can assume that all reports refer to the same concept: significant neurological losses due to complications of the LVAD and/or anticoagulation impairing the daily activity of the patient and, therefore, his or her quality of life (QoL). For this reason, these rates are the absolute minimum that seems to be critical for counselling families prior to implantation and managing patients while on the device.
The seventh INTERMACS report mentions a neurological event rate of 20.4% in paediatric patients [9] , which was confirmed by the PediMACS data with 26% cerebrovascular accidents [23] . There might be substantial differences in paediatric patients supported by VAD in terms of the concerned device, age, BSA, percentage of biventricular support and single ventricular physiology. Neurological dysfunctions including ischaemic stroke and haemorrhagic stroke were reported to be 3 times lower in patients with CFVADs compared to those in the pulsatile group [21] . In our analyses, we excluded not only pulsatile devices but also intracorporeal biventricular VADs. These analyses found an overall incidence of ischaemic or haemorrhagic stroke of 7% in patients younger than 19 years of age (0.1 events per patient-year). This incidence is comparable to the US data (PediMACS) reporting neurological dysfunction in 9 of 109 patients on CFVAD support [21] .
Other trials investigating children on CFVADs described rates of cerebrovascular accidents to be between 0% and 16% [14-16, 20, 24-26] . None of the reports distinguished between implants according to manufacturing recommendations or off-label use in patients <1.2 m 2 . This analysis found a cerebral stroke rate of 0.1 events per patient-year without finding any significant difference between the BSA groups. Interestingly, 75% of patients suffering from cerebral stroke had been treated previously for pump thrombosis (thrombolysis or device exchange). Although the cerebral stroke rates were low, the events led to death in threefourths of the patients, thus becoming the most frequent cause of death (37%). The other fatal causes of death were multiorgan failure (25%), right ventricular failure (25%) and infections (12%). Compared with the PediMACS report (which focused on CF devices) [21] , our cohort was comparable at 6 months (8% vs 9%) and 12 months (11% vs 12%). One of the main differences is the percentage of patients who received transplants: although 61% of the US patients had a transplant within the first 6 months, only 25% patients in Europe received a transplant during the same period. This difference indicates (as previously known) the lack of suitable organ donors in Europe and the longer support times in Europe. On the other hand, this difference also highlights the importance of QoL in these patients, and discharge is an important part of QoL. In this cohort, 72% of the patients were discharged (compared with PediMACS, where 45% were discharged). This outcome, in combination with a low cerebral stroke rate, justifies the increasing use of adult-approved CF devices in children.
A few other interesting findings emerged from in this study: although all the younger patients (Group 1) were taking inotropes and had a lower INTERMACS level prior to LVAD placement, only 80% of the patients in Group 2 received inotropes and also had a significantly higher INTERMACS level. One may speculate that physicians are more reluctant to implant intracorporeal LVADs, because placement and management in young children are more complex than in grown-up children. All fatalities in the younger patients occurred within 36 days of the LVAD procedure. The other interesting finding is that there were no differences in the estimated flow rates between the groups. One would expect lower flow rates for younger patients, but this was not the case. There were no differences concerning foetal right ventricular failure or the use of a right VAD between the groups. This point should be investigated further, because the authors provided no explanation for these topics in this project. On the other hand, the high flow rates might explain, in part, why the incidence of pump thrombosis and cerebral stroke did not differ between the groups and was comparable to that in adults. All patients (n) 5 1 1 3 3 8 Cerebral strokes, a n (%)
Including ischaemic or haemorrhagic cerebral stroke.
Limitations
This study has several limitations inherent to retrospective data collection, and we must mention that not all European centres report their data to EUROMACS. The volume in European centres is in most cases smaller than that in US centres, and it is clear that all of the centres experienced a 'learning curve'. The volume handled by the different centres and the starting point of CF LVAD implantation may be seen in Supplementary Material, File S3. The biggest drawback is that the event rate was too small to conduct a proper risk factor or multivariate analysis. As in all registries, events may be under-reported. The report could be biased by the fact that not all patients from the participating centres were included, and some centres may not have sent their reports at all due to unfavourable results. The EUROMACS Registry tries to prevent this by applying several quality control methods. The definition of cerebral strokes covers a wide range of symptoms and, because this is a database analysis, it is possible that we could have missed some mild symptoms without a relevant impact on QoL.
The cut-off point of 1.2 m 2 for the BSA was chosen because of the approval of 1 device, but this might differ for other devices. Furthermore, the number of young children (BSA <1.2 m 2 ) was low (n = 13). To rule out that deaths and neurological events cluster around a low BSA, we stratified the results according to the BSA (see Supplementary Material, File S4). Despite these limitations, this is the first report of children supported with CF LVADs that has emerged from the EUROMACS database, thereby adding further information to that already published concerning the US cohort (PediMACS).
CONCLUSION
The incidence of cerebral strokes in children with intracorporeal VADs (0.1 per patient-year) seems to be low irrespective of whether the patients have a BSA above or below 1.2 m 2 .
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